SYNERGY, SOLUTIONS, SUCCESS
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
|
||||||||||
 |
 |
 |
|
|||||||||
 |
|
|||||||||||
 |
 |
 |
|
|||||||||
 |
|
|||||||||||
 |
 |
|
||||||||||
 |
|
|||||||||||
 |
 |
|
||||||||||
 |
|
|||||||||||
 |
  |
|
||||||||||
 |
|
|||||||||||
 |
 |
|
||||||||||
 |
|
|||||||||||
 |
 |
|
||||||||||
 |
|
|||||||||||
 |
|
|||||||||||
 |
|
|||||||||||
SBIR & STTR Funded Business
Recipient:
NIH SBIR Phase II Grant:
"Tissue Products and Kits from Renal Disease"
STTR Phase I Grant:
"Commercialization of Embryonic Kidney Cell Lines"
Sheep Anti-Thy1 antibody to induce mesangial proliferative glomerulonephritis
Sheep Anti-Fx1A antibody to induce experimental membranous nephritis
Probetex, Inc. is a bio-technology and contract research organization providing reagents, biological samples, and services for the investigation of experimental models of disease. The company's current focus is on renal diseases, but will soon expand to include liver cardiovascular, and lung diseases.
Company Highlights:
Projects:
Chemokine-targeted macrophage depletion ameliorates experimental mesangio-proliferative glomerulonephritis. In partnership with Osprey Pharmaceuticals Limited. Renal Week. San Francisco, CA. November 4, 2007 Abstract
Molecular mechanisms underlying kidney damage in a rat anti thy-1 model of glomerulonephritis: A Gene expression analysis. J. Am. Soc.Nephrol. 15:435A,2004. In partnership with CuraGen Corporation Abstract
Probetex licenses kidney cell lines: White paper
NEW! Kidney cell lines
Glomerular mesangial
Glomerular epithelial
Glomerular endothelial
Embryonic kidney stem cells
Please inquire
Meetings & Events:
Home | Products | Services | Resources | Protocols | About Us | FAQ | Links | Contact Webmaster